// App-Quantinova.ai

309 : Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.

Researchers

Presenter

  • Eric Raymond

Principal Investigators

  • Daniel Castellano

  • Juan W. Valle

  • Pascal Hammel

  • Jean-Luc Raoul

  • Aaron Vinik

  • Yung-Jue Bang

  • Se-Hoon Lee

  • Ivan Borbath

  • Catherine Lombard Bohas

  • Peter Metrakos

  • Denis Michel Smith

  • Jen-Shi Chen

  • Jean Francois Seitz

  • Shem Patyna

  • Xin Huang

  • Jack Ishak

  • Sandrine J. Faivre

  • Philippe B. Ruszniewski

Medical Centers

  • Beaujon Hospital, Clichy, France

  • University Hospital Timone, Marseille, France

  • University Hospital 12 de October, Madrid, Spain

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Institut Paoli-Calmettes, Marseille, France

  • Eastern Virginia Medical School, Norfolk, VA

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Edouard-Herriot Hospital, Hospices Civils de Lyon, Lyon, France

  • McGill University Health Centre, Montreal, QC, Canada

  • Pellegin University Hospital, Bordeaux, France

  • Chang Gung Memorial Hospital, Taipei, Taiwan

  • CHU La Timone, Marseille, France

  • Pfizer Oncology, La Jolla, CA

  • Evidera, St-Laurent, QC, Canada

Locations

  • France

  • Spain

  • United Kingdom

  • United States

  • Republic of South Korea

  • Belgium

  • Canada

  • Taiwan

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic Neuroendocrine Tumors

Biomarkers

  • N/A

Drug/Treatment

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • III

Study Id's

  • NCT00428597

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved